Report Overview

The UK Alport Syndrome Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Alport syndrome is a rare genetic disorder caused by the gene mutation of COL4A3, COL4A4, or COL4A5 & characterized by progressive kidney disease and abnormalities of the inner ear and the eye. Two major types of Alport syndrome are Autosomal Dominant Alport Syndrome (ADAS), and Autosomal Recessive Alport Syndrome (ARAS). The hallmark of the disease is the presence of blood in the urine (haematuria) early in life, with progressive decline in kidney function (kidney insufficiency) that ultimately results in kidney failure, especially in affected males.

Both males and females with ARAS develop kidney failure, often in the teenage years or early adulthood. ADAS tends to be a slowly progressive disorder in which renal insufficiency does not develop until well into adulthood. Individuals with Alport syndrome can also develop progressive hearing loss of varying severity and abnormalities of the eyes that usually do not result in impaired vision.

Alports syndrome is not common in the UK. One or two out of 100 people starting dialysis have Alports syndrome, with a frequency in the general population of about 1 in 5,000, to 1 in 10,000. The inheritance of Alports syndrome nearly applies to 9 out of 10 families. Nearly all the men and about 1 in 10 women with Alports syndrome develop kidney failure. Most men develop kidney failure between the ages of 15 and 30, though in some families this is delayed to 50-70 years. About 6 out of 10 women may develop protein in the urine. Although protein in the urine suggests a risk for progression to kidney failure, in many cases the kidney function remains normal and only about 1 in 10 women with Alports syndrome ever need dialysis or a kidney transplant.

Market Growth Drivers

Alport syndrome is a major cause of kidney disease among the patient population. The rise in the prevalence of genetic disorders is likely to augment the Alport syndrome market over the forecast period Hence, faster adoption and availability of diagnostic tests across the market are anticipated to augment the Alport syndrome market.

Huge investments by the key players and initiatives by governments for research and development of drugs for managing Alport syndrome and its symptoms are likely to propel the Alport syndrome market. With strong research and development initiatives, most of the companies are focusing on innovative and cost-effective drug development.

Market Restraints

However, the high cost of treatment, less awareness about the syndrome, and its lower treatment rates act as major restraints of the Alport syndrome market.